Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases Source: Eur Respir Rev, 28 (153) 190109; 10.1183/16000617.0109-2019 Year: 2019
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases Source: Eur Respir J, 54 (3) 1900161; 10.1183/13993003.00161-2019 Year: 2019
Progressive fibrosing ILDs Source: Virtual Congress 2021 – Interstitial lung diseases Year: 2021
The natural history of progressive fibrosing interstitial lung diseases Source: Eur Respir J, 55 (6) 2000085; 10.1183/13993003.00085-2020 Year: 2020
Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019
Reply to comment on “The natural history of progressive fibrosing interstitial lung diseases” Source: Eur Respir J, 56 (6) 2003967; 10.1183/13993003.03967-2020 Year: 2020
Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends Year: 2021
Genetic susceptibilty and manifestation of progressive fibrosing interstitial lung diseases. Source: Virtual Congress 2020 – New clinical insights into idiopathic pulmonary fibrosis Year: 2020
Prevalence of progressive fibrosing interstitial lung disease Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018
Comment on “The natural history of progressive fibrosing interstitial lung diseases” Source: Eur Respir J, 56 (6) 2003508; 10.1183/13993003.03508-2020 Year: 2020
Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin? Year: 2020
Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature Source: Eur Respir Rev 2012 21: 355-361 Year: 2012
Experience with antifibrotics treatment in progressive interstitial lung diseases non-IPF Source: Virtual Congress 2021 – Clinical evolution, management and outcomes of patients with rare diffuse parenchymal lung diseases Year: 2021
The features of the course of cryptogenic fibrosing alveolitis in women Source: Eur Respir J 2002; 20: Suppl. 38, 59s Year: 2002
Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015
Specific features of the course of cryptogenic fibrosing alveolitis in pregnancy Source: Eur Respir J 2001; 18: Suppl. 33, 150s Year: 2001
Idiopathic fibrosing alveolitis (IFA) as a background for the lung cancer development Source: Eur Respir J 2002; 20: Suppl. 38, 479s Year: 2002
Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005
ERS guidelines on treatment of sarcoidosis Source: ERS webinar 2021: ERS guidelines on treatment of sarcoidosis Year: 2021
Rituximab in the management of idiopathic inflammatory myopathies complicated by interstitial lung disease Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017